MY144620A - Recombinant antibodies and fragments which recognize n glycolil gm3 ganclioside and its use in diagnosis and treatment of tumors - Google Patents
Recombinant antibodies and fragments which recognize n glycolil gm3 ganclioside and its use in diagnosis and treatment of tumorsInfo
- Publication number
- MY144620A MY144620A MYPI20041468A MYPI20041468A MY144620A MY 144620 A MY144620 A MY 144620A MY PI20041468 A MYPI20041468 A MY PI20041468A MY PI20041468 A MYPI20041468 A MY PI20041468A MY 144620 A MY144620 A MY 144620A
- Authority
- MY
- Malaysia
- Prior art keywords
- glycolil
- fragments
- diagnosis
- ganclioside
- tumors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20030092A CU23403A1 (es) | 2003-04-23 | 2003-04-23 | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY144620A true MY144620A (en) | 2011-10-14 |
Family
ID=40261249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20041468A MY144620A (en) | 2003-04-23 | 2004-04-22 | Recombinant antibodies and fragments which recognize n glycolil gm3 ganclioside and its use in diagnosis and treatment of tumors |
Country Status (32)
| Country | Link |
|---|---|
| EP (1) | EP1623997B1 (fr) |
| JP (1) | JP2006524194A (fr) |
| KR (1) | KR20060006937A (fr) |
| CN (2) | CN1809592A (fr) |
| AR (1) | AR044076A1 (fr) |
| AU (1) | AU2004232391B2 (fr) |
| BR (1) | BRPI0409664A (fr) |
| CA (1) | CA2523449C (fr) |
| CL (1) | CL2004000843A1 (fr) |
| CR (1) | CR8105A (fr) |
| CU (1) | CU23403A1 (fr) |
| EA (1) | EA008353B1 (fr) |
| ES (1) | ES2535813T3 (fr) |
| GE (1) | GEP20084476B (fr) |
| HK (1) | HK1183492A1 (fr) |
| HR (1) | HRP20050922A2 (fr) |
| HU (1) | HUE025266T2 (fr) |
| IL (1) | IL171541A (fr) |
| LT (1) | LT5353B (fr) |
| LV (1) | LV13427B (fr) |
| MX (1) | MXPA05011368A (fr) |
| MY (1) | MY144620A (fr) |
| NZ (1) | NZ543345A (fr) |
| PE (1) | PE20050422A1 (fr) |
| PL (1) | PL1623997T3 (fr) |
| RS (2) | RS20110319A3 (fr) |
| SI (1) | SI1623997T1 (fr) |
| TN (1) | TNSN05274A1 (fr) |
| TW (1) | TWI343923B (fr) |
| UY (1) | UY28289A1 (fr) |
| WO (1) | WO2004094477A1 (fr) |
| ZA (1) | ZA200509457B (fr) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2350454T3 (es) | 1998-11-27 | 2011-01-24 | Ucb Pharma S.A. | Composiciones y métodos para incrementar la mineralización de la sustancia ósea. |
| ES2586401T3 (es) | 2003-06-16 | 2016-10-14 | Ucb Pharma S.A. | Anticuerpos específicos para la esclerostina y métodos para aumentar la mineralización ósea |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| ES2773031T3 (es) | 2010-05-14 | 2020-07-09 | Amgen Inc | Formulaciones de anticuerpos anti-esclerostina a alta concentración |
| CA2828000A1 (fr) | 2011-03-01 | 2012-09-07 | Amgen Inc. | Agents liants bispecifiques |
| AP3981A (en) | 2011-03-25 | 2017-01-05 | Amgen Inc | Anti - sclerostin antibody crystals and formulations thereof |
| AU2012290083B2 (en) | 2011-08-04 | 2017-07-20 | Amgen Inc. | Method for treating bone gap defects |
| CU24070B1 (es) * | 2011-12-27 | 2015-01-29 | Ct De Inmunología Molecular | Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3) |
| SG11201403718YA (en) | 2011-12-28 | 2014-07-30 | Amgen Inc | Method of treating alveolar bone loss through the use of anti-sclerostin antibodies |
| CU24120B1 (es) * | 2012-03-01 | 2015-08-27 | Ct De Inmunología Molecular | Anticuerpos recombinantes con especificidad dual por los gangliósidos n-acetil gm3 y n-glicolil gm3 |
| WO2014006100A1 (fr) | 2012-07-05 | 2014-01-09 | Ucb Pharma S.A. | Traitement de maladies osseuses |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| CN106163547A (zh) | 2014-03-15 | 2016-11-23 | 诺华股份有限公司 | 使用嵌合抗原受体治疗癌症 |
| MA41142A (fr) | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
| CN104651314B (zh) | 2015-02-14 | 2018-06-19 | 百泰生物药业有限公司 | 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子 |
| EP3286211A1 (fr) | 2015-04-23 | 2018-02-28 | Novartis AG | Traitement du cancer à l'aide de protéine récepteur antigénique chimérique et un inhibiteur de protéine kinase |
| WO2017027392A1 (fr) | 2015-08-07 | 2017-02-16 | Novartis Ag | Traitement du cancer à l'aide des protéines de récepteur cd3 chimères |
| CA3009709A1 (fr) | 2015-12-30 | 2017-07-06 | Novartis Ag | Therapies a base de cellules effectrices immunitaires dotees d'une efficacite accrue |
| GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| EP3574005B1 (fr) | 2017-01-26 | 2021-12-15 | Novartis AG | Compositions de cd28 et procédés pour une thérapie à base de récepteur antigénique chimérique |
| EP3577134A1 (fr) | 2017-01-31 | 2019-12-11 | Novartis AG | Traitement du cancer à l'aide de protéines chimères du récepteur de lymphocytes t ayant de multiples spécificités |
| US20210040205A1 (en) | 2017-10-25 | 2021-02-11 | Novartis Ag | Antibodies targeting cd32b and methods of use thereof |
| US20200370012A1 (en) | 2017-10-25 | 2020-11-26 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| CU20170173A7 (es) * | 2017-12-27 | 2019-11-04 | Ct Inmunologia Molecular | Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras |
| WO2019191534A1 (fr) | 2018-03-30 | 2019-10-03 | Amgen Inc. | Variants d'anticorps anti-c-terminal |
| EP3784351A1 (fr) | 2018-04-27 | 2021-03-03 | Novartis AG | Thérapies reposant sur des cellules car-t présentant une efficacité améliorée |
| WO2019227003A1 (fr) | 2018-05-25 | 2019-11-28 | Novartis Ag | Polythérapie comprenant des thérapies par récepteur antigénique chimérique (car) |
| US20210123075A1 (en) | 2018-06-08 | 2021-04-29 | Novartis Ag | Compositions and methods for immunooncology |
| KR102344948B1 (ko) * | 2018-09-03 | 2021-12-28 | 세종대학교산학협력단 | 인간 순수만능줄기세포에 특이적인 단일클론항체 n1-a4 |
| CA3123511A1 (fr) | 2018-12-20 | 2020-06-25 | Novartis Ag | Schema posologique et combinaison pharmaceutique comprenant des derives de 3-(1-oxoisoindoline-2-yl) piperidine-2,6-dione |
| EA202192019A1 (ru) | 2019-02-15 | 2021-11-02 | Новартис Аг | Производные 3-(1-оксо-5-(пиперидин-4-ил)изоиндолин-2-ил)пиперидин-2,6-диона и пути их применения |
| CN110208409A (zh) * | 2019-06-05 | 2019-09-06 | 中国海洋大学 | 一种乳腺癌的生物标志物及其应用 |
| WO2021123908A1 (fr) | 2019-12-20 | 2021-06-24 | Ludwig Institute For Cancer Research Ltd | Thérapie à base de lymphocytes car-t ciblant l'antigène ngcgm3 |
| WO2021123996A1 (fr) | 2019-12-20 | 2021-06-24 | Novartis Ag | Utilisations d'anticorps anti-tgf-bêtas et inhibiteurs de point de contrôle pour le traitement des maladies prolifératives |
| WO2024089639A1 (fr) | 2022-10-26 | 2024-05-02 | Novartis Ag | Formulations lentivirales |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU669124B2 (en) * | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
| KR100367948B1 (ko) * | 1994-01-25 | 2003-07-12 | 엘란 파마슈티칼스, 인크. | 백혈구부착분자vla-4에대한인체화된항체 |
| CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
| WO1996013594A1 (fr) | 1994-10-28 | 1996-05-09 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Fragments d'anticorps a specificite tumorale, proteines de fusion, et leurs utilisations |
| NZ311174A (en) * | 1995-06-30 | 1999-04-29 | Mochida Pharm Co Ltd | Anti-fas ligand antibody which suppresses fas ligand-induced apoptosis in cells and method of assaying a fas ligand using the anti-fas ligand antibody |
| US5834597A (en) * | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| CU22731A1 (es) * | 1998-02-05 | 2002-02-28 | Centro Inmunologia Molecular | Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen |
-
2003
- 2003-04-23 CU CU20030092A patent/CU23403A1/es unknown
-
2004
- 2004-04-21 PE PE2004000397A patent/PE20050422A1/es not_active Application Discontinuation
- 2004-04-21 CL CL200400843A patent/CL2004000843A1/es unknown
- 2004-04-22 GE GEAP20049062A patent/GEP20084476B/en unknown
- 2004-04-22 MX MXPA05011368A patent/MXPA05011368A/es active IP Right Grant
- 2004-04-22 SI SI200432242T patent/SI1623997T1/sl unknown
- 2004-04-22 AU AU2004232391A patent/AU2004232391B2/en not_active Ceased
- 2004-04-22 HU HUE04728755A patent/HUE025266T2/en unknown
- 2004-04-22 CN CNA2004800174578A patent/CN1809592A/zh active Pending
- 2004-04-22 KR KR1020057020182A patent/KR20060006937A/ko not_active Application Discontinuation
- 2004-04-22 ES ES04728755.2T patent/ES2535813T3/es not_active Expired - Lifetime
- 2004-04-22 EP EP04728755.2A patent/EP1623997B1/fr not_active Expired - Lifetime
- 2004-04-22 PL PL04728755T patent/PL1623997T3/pl unknown
- 2004-04-22 JP JP2006504218A patent/JP2006524194A/ja active Pending
- 2004-04-22 CN CN201210517262.6A patent/CN103012586B/zh not_active Expired - Fee Related
- 2004-04-22 WO PCT/CU2004/000006 patent/WO2004094477A1/fr active IP Right Grant
- 2004-04-22 EA EA200501653A patent/EA008353B1/ru not_active IP Right Cessation
- 2004-04-22 BR BRPI0409664-9A patent/BRPI0409664A/pt not_active Application Discontinuation
- 2004-04-22 CA CA2523449A patent/CA2523449C/fr not_active Expired - Lifetime
- 2004-04-22 MY MYPI20041468A patent/MY144620A/en unknown
- 2004-04-22 NZ NZ543345A patent/NZ543345A/en not_active IP Right Cessation
- 2004-04-22 RS RS20110319A patent/RS20110319A3/en unknown
- 2004-04-22 TW TW093111267A patent/TWI343923B/zh not_active IP Right Cessation
- 2004-04-22 RS YU20050795A patent/RS51853B/en unknown
- 2004-04-23 UY UY28289A patent/UY28289A1/es not_active Application Discontinuation
- 2004-04-23 AR ARP040101389A patent/AR044076A1/es active IP Right Grant
-
2005
- 2005-10-21 TN TNP2005000274A patent/TNSN05274A1/en unknown
- 2005-10-21 HR HR20050922A patent/HRP20050922A2/xx not_active Application Discontinuation
- 2005-10-23 IL IL171541A patent/IL171541A/en active IP Right Grant
- 2005-11-21 LT LT2005101A patent/LT5353B/lt not_active IP Right Cessation
- 2005-11-22 LV LVP-05-152A patent/LV13427B/en unknown
- 2005-11-22 ZA ZA200509457A patent/ZA200509457B/en unknown
- 2005-11-25 CR CR8105A patent/CR8105A/es not_active Application Discontinuation
-
2013
- 2013-09-19 HK HK13110760.2A patent/HK1183492A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY144620A (en) | Recombinant antibodies and fragments which recognize n glycolil gm3 ganclioside and its use in diagnosis and treatment of tumors | |
| MX2009009926A (es) | Anticuerpo tumor-especifico humano monoclonal. | |
| PL367831A1 (en) | Recombinant tumor specific antibody and use thereof | |
| WO2011163401A3 (fr) | Antigènes et anticorps spécifiques des cancers du côlon et du pancréas | |
| MX2013011363A (es) | Anticuerpos para peptidos citosolicos. | |
| TNSN05300A1 (en) | Treatment with anti-vegf antibodies | |
| EP1996716A4 (fr) | Anticorps modifies diriges contre l'antigene de cellules souches prostatiques servant a cibler le cancer | |
| EP1442295A4 (fr) | Essais diagnostiques bases sur la periostine | |
| MY157372A (en) | Immunotherapeutic combinations for the treatment of tumors that over-express gangliosides | |
| MX340724B (es) | Terapia anti-angiogenesis para el tratamiento del cancer de mama. | |
| WO2006083852A3 (fr) | Luca2 et anticorps s'y liant | |
| WO2006076584A3 (fr) | Antigène kid31 (carboxypeptidase m) et anticorps de liaison à celui-ci | |
| IL163902A0 (en) | Antibodies against cancer antigen tmeff2 and uses thereof | |
| SG146644A1 (en) | Kid3 and kid3 antibodies that bind thereto | |
| MX2022004194A (es) | Anticuerpos contra el receptor de virus de la polio (pvr) y usos de los mismos. | |
| MX2023001776A (es) | Anticuerpos contra ilt2 y uso de los mismos. | |
| EP2277918A3 (fr) | Antigène peptide mhc classe I et II dérivé d'une tumeur antigène 5t4 | |
| IL138021A0 (en) | High affinity humanized anti-tag-72 monoclonal antibodies | |
| TN2012000151A1 (en) | Chimeric antibodies specific for cd151 and use thereof in the treatment of cancer | |
| AU2018256601A1 (en) | Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer | |
| ECSP056112A (es) | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores | |
| TN2013000387A1 (en) | T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2 |